Receptor News and Research

RSS

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.

3 May 2010

Protein test to determine response of lung cancer patients to erlotinib

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Majority of patients who appear healthy may be at risk for cardiovascular disease

Three separate studies announced today at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) examined the cardiovascular consequences of relatively healthy patients - those who were asymptomatic and not classified as hypertensive or diabetic - and found that many patients who appear healthy may still be at risk for cardiovascular disease.

3 May 2010

Researchers discover a new driving force behind cancer growth

Researchers from the University of Leeds, UK, the Charit- University Medical School and the Max Delbr-ck Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.

3 May 2010

Smoking can increase risk of second cancer in breast cancer survivors

Women who survive early-stage breast cancer and smoke have an increased chance of developing a new second cancer in their other breast or elsewhere.

3 May 2010

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Tumor cell factories may be difficult to defeat: Researchers

Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells.

29 Apr 2010

Adolor's ENTEREG first-quarter net product sales increases to $5.3 million

Adolor Corporation today reported a net loss of $9.6 million, or $(0.21) per basic and diluted share, for the three months ended March 31, 2010, compared to a net loss of $13.2 million, or $(0.28) per basic and diluted share, for the three months ended March 31, 2009.

29 Apr 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.

29 Apr 2010

FXR can slow proliferation of tamoxifen-resistant breast cancer cells: Study

A receptor that is present in the nucleus of cells can, when activated, slow the growth of tamoxifen-resistant breast cancer cells, a new study found. The study built on the recent discovery that farnesoid X receptor — a nuclear receptor found mainly in the liver — is found in breast cancer tissue.

28 Apr 2010

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives - experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

28 Apr 2010

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Usually when all else fails with a technical device, a "reset" button can be pressed, preventing a glitch from going any further. What if that could be done with threats to a person's health? Investigators from The Cancer Institute of New Jersey and the Environmental & Occupational Health Sciences Institute which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, have discovered that a form of a dietary trace element known as selenium can help reset a cell's "biological clock" when it is disrupted by a chemical cancer-causing agent (carcinogen).

28 Apr 2010

Receptor News and Research

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Protein test to determine response of lung cancer patients to erlotinib

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Majority of patients who appear healthy may be at risk for cardiovascular disease

Researchers discover a new driving force behind cancer growth

Smoking can increase risk of second cancer in breast cancer survivors

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

REGN reports net loss of $30.5M for first-quarter 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Canadian researchers identify new therapeutic target for lung cancer

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Tumor cell factories may be difficult to defeat: Researchers

Adolor's ENTEREG first-quarter net product sales increases to $5.3 million

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

FXR can slow proliferation of tamoxifen-resistant breast cancer cells: Study

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News